ORAI1 and acute pancreatitis: Likewise, mitigation of SNI-induced pain hypersensitivity was replicated by CM4620, a small-molecule Orai1 antagonist that is currently in clinical trials for mitigating inflammation in human patients with acute pancreatitis and COVID-19 pneumonia (33, 34).